Search

Author/Creator Sebestyen, Zsolt

1. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells. (2nd January 2018)

Authors:
de Bruin, Renée C. G.; Veluchamy, John P.; Lougheed, Sinéad M.; Schneiders, Famke L.; Lopez-Lastra, Silvia; Lameris, Roeland; Stam, Anita G.; Sebestyen, Zsolt; Kuball, Jürgen; Molthoff, Carla F. M.; Hooijberg, Erik; Roovers, Rob C.; Santo, James P. Di; van Bergen en Henegouwen, Paul M. P.; Verheu...
Journal:
Oncoimmunology
Issue:
Volume 7:Number 1(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells. Issue 1 (12th March 2019)

Authors:
Johanna, Inez; Straetemans, Trudy; Heijhuurs, Sabine; Aarts-Riemens, Tineke; Norell, Håkan; Bongiovanni, Laura; de Bruin, Alain; Sebestyen, Zsolt; Kuball, Jürgen
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 7:Issue 1(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. (4th November 2015)

Authors:
Drent, Esther; Groen, Richard; Noort, Willy; van Bueren, Jeroen Lammerts; Parren, Paul; Kuball, Jürgen; Sebestyen, Zsolt; van de Donk, Niels; Martens, Anton; Lokhorst, Henk; Mutis, Tuna
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Issue 2 (December 2015)

Authors:
Drent, Esther; Groen, Richard; Noort, Willy; van Bueren, Jeroen; Parren, Paul; Kuball, Jürgen; Sebestyen, Zsolt; van de Donk, Niels; Martens, Anton; Lokhorst, Henk; Mutis, Tuna
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3:Issue 2(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic mice. Issue 6 (5th February 2020)

Authors:
Johanna, Inez; Hernández-López, Patricia; Heijhuurs, Sabine; Bongiovanni, Laura; de Bruin, Alain; Beringer, Dennis; van Dooremalen, Sanne; Shultz, Leonard D.; Ishikawa, Fumihiko; Sebestyen, Zsolt; Straetemans, Trudy; Kuball, Jürgen
Journal:
Journal of leukocyte biology
Issue:
Volume 107:Issue 6(2020)
Page Start:
1069
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. TEG011 persistence averts extramedullary tumor growth without exerting off‐target toxicity against healthy tissues in a humanized HLA‐A*24:02 transgenic mice. Issue 6 (5th February 2020)

Authors:
Johanna, Inez; Hernández‐López, Patricia; Heijhuurs, Sabine; Bongiovanni, Laura; de Bruin, Alain; Beringer, Dennis; van Dooremalen, Sanne; Shultz, Leonard D.; Ishikawa, Fumihiko; Sebestyen, Zsolt; Straetemans, Trudy; Kuball, Jürgen
Journal:
Journal of leukocyte biology
Issue:
Volume 107:Issue 6(2020)
Page Start:
1069
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗